Vertex says it has updated an R&D collaboration with Cystic Fibrosis Foundation Therapeutics (CFFT) stretching back more than a decade.
Under the updated Research, Development and Commercialization Agreement, disclosed in a regulatory filing yesterday, CFFT—the Foundation’s nonprofit drug discovery and development affiliate—agreed to pay Vertex $75 million upfront, as well as up to $6 million annually toward development funding.